Scholar Rock Holding (SRRK) closed at $44.54 on November 16, 2026, up 3.1% from the previous close, on volume of 2,449,908 shares (30-day average 1,662,526).
Data as of November 16, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 9, 2026 | Seagull Ratio With Put Spread | 20-Nov-2640 P : 45[3x] P : 55[4x] C | 2,000 |
| 2-2 | The next 1 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 16, 2026. See the largest for 5, 30, 60 and 90 days
J.P. Morgan Remains a Buy on Scholar Rock Holding (SRRK)
TipRanks (Tue, 17-Nov 8:36 AM ET)
Scholar Rock to Present at Upcoming Investor Conferences
Business Wire (Tue, 17-Nov 8:00 AM ET)
Scholar Rock Earnings Call Highlights ISEMBYLD Launch Momentum
TipRanks (Sat, 14-Nov 8:12 PM ET)
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire (Fri, 13-Nov 4:15 PM ET)
Analysts Offer Insights on NA Companies: Scholar Rock Holding (SRRK) and Builders Firstsource (BLDR)
TipRanks (Thu, 12-Nov 3:20 AM ET)
Scholar Rock Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Business Wire (Tue, 10-Nov 7:00 AM ET)
Scholar Rock to Report Third Quarter 2026 Financial Results on November 10, 2026
Business Wire (Tue, 20-Oct 8:00 AM ET)
Business Wire (Thu, 8-Oct 8:00 AM ET)
Kuehn Law Encourages Investors of Scholar Rock Holding Corp to Contact Law Firm
PRNewswire (Wed, 30-Sep 9:56 AM ET)
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
Scholar Rock Holding trades on the NASDAQ stock market under the symbol SRRK.
As of November 17, 2026, SRRK stock price declined to $44.31 with 597,432 million shares trading.
SRRK has a beta of 0.73, meaning it tends to be less sensitive to market movements. SRRK has a correlation of 0.03 to the broad based SPY ETF.
SRRK has a market cap of $5.41 billion. This is considered a Mid Cap stock.
Last quarter Scholar Rock Holding reported $600,000 in Revenue and -$.81 earnings per share. This beat revenue expectation by $321,064 and exceeded earnings estimates by $.04.
In the last 3 years, SRRK traded as high as $61.76 and as low as $6.76.
The top ETF exchange traded funds that SRRK belongs to (by Net Assets): VTI, IWM, XBI, VB, VXF.
SRRK has outperformed the market in the last year with a price return of +18.4% while the SPY ETF gained +9.8%. However, in the short term, SRRK had mixed performance relative to the market. It has underperformed in the last 3 months, returning -15.6% vs -5.7% return in SPY. But in the last 2 weeks, SRRK shares have fared better than the market returning +3.3% compared to SPY -2.9%.
SRRK support price is $43.27 and resistance is $45.81 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SRRK shares will trade within this expected range on the day.